Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Na Lou

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2016
The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLCSi-Yang Liu, Lan-Ying Gou, An-Na Li, et al.
BMC Cancer|November 28, 2018
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpressionRui-Lian Chen, Jun Zhao, Xu-Chao Zhang, et al.
Oncotarget|June 5, 2016
The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancerLan-Ying Gou, An-Na Li, Jin-Ji Yang, et al.
Oncotarget|August 18, 2016
Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterationsNa-Na Lou, Xu-Chao Zhang, Hua-Jun Chen, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2016
The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLCSi-Yang Liu, Lan-Ying Gou, An-Na Li, et al.
BMC Cancer|November 28, 2018
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpressionRui-Lian Chen, Jun Zhao, Xu-Chao Zhang, et al.
Oncotarget|June 5, 2016
The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancerLan-Ying Gou, An-Na Li, Jin-Ji Yang, et al.
Oncotarget|August 18, 2016
Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterationsNa-Na Lou, Xu-Chao Zhang, Hua-Jun Chen, et al.
Pageof 3